MicroRNA expressions in stool and serum of patients with colorectal cancer and its application to diagnosis

点击翻译按钮获取中文摘要

We evaluated the fecal expression of miR-19a, miR-20a, miR-21, miR-92a and miR-106a for 138 patients with colorectal cancer (CRC), 26 patients with advanced adenoma (AA) and 126 control subjects, and compared fecal miRNA assay with a single FIT on same stool samples. Fecal miR-19a, miR-20a, miR-21, miR-92a and miR-106a expressions were significantly higher in CRC and AA than in control. The overall sensitivity of the multi-panel of fecal miRNAs was lower than that of FIT in CRC (60.9% vs. 66.7%, P=0.32). However among subjects with AA, stage 0 and stage I, the sensitivity of the multi-panel of fecal miRNAs was significantly higher than that of FIT (51.4% vs.33.3%, P=0.03). Fecal multi-markers miRNA panel may be useful for screening of colorectal early tumors.